Athenex Inc
Most Recent
Company & Industry OverviewsAthenex’s Product Groups and Geographic Performance
The majority of Athenex’s revenues in Q1 2018 came from API sales, commercial product sales, and license fees.
Company & Industry OverviewsA Focus on Pipeline Expansion Bodes Well for Athenex
Athenex announced a strategic investment of $100 million from Perceptive Advisors.
Company & Industry OverviewsHow Athenex’s Business Segments Performed in Q1 2018
Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform.
Company & Industry OverviewsAnalyzing Athenex’s Cash Flows
In fiscal 2017, Athenex (ATNX) incurred interest expenses of $5.9 million—compared to $1.8 million in fiscal 2016.
Company & Industry OverviewsHow’s Athenex’s Financial Performance?
In fiscal 2017, Athenex (ATNX) generated total revenues of $38 million—compared to $20.5 million in fiscal 2016.
Company & Industry OverviewsUnderstanding Athenex’s Research Platforms
Athenex’s (ATNX) Orascovery platform is based on the P-gp pump inhibitor molecule, HM30181A. Athenex licensed the molecule from Hanmi.
Company & Industry OverviewsAnalysts’ Ratings for Athenex and Its Peers in March
Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating.